about
P184
The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysisAdhiron: a stable and versatile peptide display scaffold for molecular recognition applicationsExploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologiesSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Regulation of Fgf10 gene expression in the prostate: identification of transforming growth factor-beta1 and promoter elementsHigh-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markersDifferential effects of transforming growth factor-beta1 on cellular proliferation in the developing prostateSonic hedgehog regulates prostatic growth and epithelial differentiationAn siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genesA place for precision medicine in bladder cancer: targeting the FGFRs.FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerAffimer proteins are versatile and renewable affinity reagentsStructure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant.FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.A high-throughput assay to identify modifiers of premature chromosome condensation.Selective and potent proteomimetic inhibitors of intracellular protein-protein interactionsDevelopment and characterisation of a 3D multi-cellular in vitro model of normal human breast: a tool for cancer initiation studiesFibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.Multidrug-resistant breast cancer: current perspectives.Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease.Chapter Eight - Ubiquitin-Mediated Regulation of Cellular Responses to Vascular Endothelial Growth Factors.Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity.Trivalent Gd-DOTA reagents for modification of proteins.The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their functionA Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer.Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.VEGFR2 Trafficking, Signaling and Proteolysis is Regulated by the Ubiquitin Isopeptidase USP8.Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.Alternative reagents to antibodies in imaging applications.VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking and proteolysis.Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases.Ultraefficient Cap-Exchange Protocol To Compact Biofunctional Quantum Dots for Sensitive Ratiometric Biosensing and Cell Imaging.Ubiquitination of basal VEGFR2 regulates signal transduction and endothelial function.Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions.Antibody mimetic receptor proteins for label-free biosensors.Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action.
P50
Q26796921-BA32A107-67E8-4CC8-90DE-B91A46925E93Q27682484-85A8D803-0577-4268-A0FE-BB8AD4296D28Q27701444-8E957603-0609-4BCA-A4AA-BB12421F3FDDQ27851612-F1477775-313B-4874-9745-D16ADA0F9291Q28238951-02E5734A-A025-44E5-867A-EBF7E4B672F9Q28539567-D6079896-3C55-4AAA-BF37-27F2A1E90E09Q28564252-8F2B4A82-CEAA-4358-9347-0560D3CEA12CQ28580501-0409D897-43C5-4214-A890-2E7F8C4DF1E6Q29144923-8B809C55-B2E0-4BC3-86A2-23DB7FC208D5Q30249143-c70c2e76-479a-e2cb-d3c7-9ca87d10d779Q33292711-7183BA06-A54C-4A9C-BD76-E3023EC7176CQ33842511-4856C615-948D-475A-A3AA-232832D6B1B2Q33913444-ABBDA072-EE64-45A2-9739-D4799A9ADAA7Q34305855-B3A5986C-4D98-4DD1-98CA-BBAB33AB3278Q34585359-4ECC52B6-4FBD-4EA7-8D22-380712583FA8Q34975412-3F244601-9969-4B9C-8C36-24C951C032BFQ35555133-977A933D-4530-4C84-822C-7AEB97941A53Q35955429-BEEE730A-3B60-499E-A00F-C15701C70B87Q37331829-4A0654F7-24BA-42C2-A2BE-4FCBFF661567Q37593383-89E3199E-3846-47F3-BB42-FF8E98F08DB5Q37692590-8F9BC3EF-19BF-4A17-9528-965C22B6C17BQ38418718-5E901C35-6A1F-4B97-A698-ADFEBAA28246Q38886250-1E8BFDAE-4FB9-4495-B400-42CF00D7C1E9Q38901167-0F55AE13-2BB5-4B4C-8E83-2ECC5F1C819CQ38920217-7A778C66-40C3-4CF6-B9F1-11F75FA97390Q39028789-EC199C46-7722-4956-BB70-0FB71F768860Q39568069-8CEEB029-A173-409D-8951-CE3D948A48C3Q39648727-2A79FB53-B5D0-453C-8A14-31B880B3E322Q39671016-F93D5F7D-62C0-4DDB-AFB5-8B80B5FDC1A8Q40198221-B92C8E73-B266-4D8C-958E-7569DBDDD03AQ40351441-1B438E99-4797-4084-A3E4-21B374402E7CQ41550210-F8FE1545-A8E1-4B0F-A218-9733BDBC35A2Q41579389-26ABA3F0-2CCA-4759-A324-C86DFE7C1C37Q41810895-A026C6AA-FF9F-4897-971F-C83825CDEA6EQ41851539-F8D89F5B-245D-4DE1-9F52-C12D91F77C19Q42264482-B2DB1E5F-2F0C-4F16-BE77-E37E7B606C53Q42513534-1F128727-48C4-40FD-AB61-E1800E2D5B03Q42544825-978EF1AB-BCA8-4C64-B2DE-863161815FDAQ43855824-F279E83D-CC2A-479F-8B6C-EF7079B545D1Q47287433-664452CA-E38F-42F9-8716-06C6975F67BA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Darren C Tomlinson
@cy
Darren C Tomlinson
@en-gb
Darren C Tomlinson
@la
Darren C. Tomlinson
@en
Darren C. Tomlinson
@nl
Darren C. Tomlinson
@sl
Darren Tomlinson
@af
Darren Tomlinson
@an
Darren Tomlinson
@ast
Darren Tomlinson
@ay
type
label
Darren C Tomlinson
@cy
Darren C Tomlinson
@en-gb
Darren C Tomlinson
@la
Darren C. Tomlinson
@en
Darren C. Tomlinson
@nl
Darren C. Tomlinson
@sl
Darren Tomlinson
@af
Darren Tomlinson
@an
Darren Tomlinson
@ast
Darren Tomlinson
@ay
altLabel
Darren Charles Tomlinson
@af
Darren Charles Tomlinson
@an
Darren Charles Tomlinson
@ast
Darren Charles Tomlinson
@ay
Darren Charles Tomlinson
@az
Darren Charles Tomlinson
@br
Darren Charles Tomlinson
@ca
Darren Charles Tomlinson
@ce
Darren Charles Tomlinson
@ceb
Darren Charles Tomlinson
@co
prefLabel
Darren C Tomlinson
@cy
Darren C Tomlinson
@en-gb
Darren C Tomlinson
@la
Darren C. Tomlinson
@en
Darren C. Tomlinson
@nl
Darren C. Tomlinson
@sl
Darren Tomlinson
@af
Darren Tomlinson
@an
Darren Tomlinson
@ast
Darren Tomlinson
@ay
P6366
P106
P1153
9740742200
P1344
P185
P2031
2003-01-01T00:00:00Z
P21
P31
P3835
darren-tomlinson
P496
0000-0003-4134-7484
P6178
0735614136.70
P6366
2063389128